search
Back to results

Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? (ADKETONE)

Primary Purpose

ADPKD

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Ketone ester
Sponsored by
Universitair Ziekenhuis Brussel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ADPKD focused on measuring ketone ester

Eligibility Criteria

16 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: - ADPKD patients (diagnosis based on genetics or imaging) ≥ 16 and ≤ 70 years. Total Kidney Volume ≥ 600 mL. eGFR (CKD-EPI) ≥ 30 ml/min/1.73m2. Normal blood glucose, HbA1C and ketones. Women of childbearing potential who are non-lactating and using an effective form of birth control. Stable disease-modifying treatment for the last 2 months. Well controlled hypertension (stable antihypertensive medications for at least 2 months). BMI > 18 < 30. Written informed consent. Exclusion Criteria: Exposure to a ketogenic diet or intermittent fasting for more than 2 weeks within 6 months before inclusion. Significant weight-loss (> 10%) within 6 months before inclusion. Diabetes mellitus. Conditions prohibiting the use of a ketogenic diet (liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/neogenesis, hyperinsulinism), based on patient history. Diagnosis with any disorder of fatty acid metabolism based on patient history. Eating disorder. Alcohol abuse. Contraindication for MRI. Participation in other interventional trial.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Ketone Ester

    Arm Description

    Up to 100g ketone ester daily for 56 days

    Outcomes

    Primary Outcome Measures

    Observance
    Objective observance (ketone body levels ≥0.8 mmol/l in ≥75% of blood measurements and ≥60% of maximal theoretic dose determined by used packages and self-report)
    Feasibility
    Patient reported feasibility, defined as a cohen d effect size of < 0.5 in the ADPKD impact scale.Both targets (observance and self-reported feasibility) must be met to reach the endpoint.

    Secondary Outcome Measures

    Total Kidney Volume
    Change in Total kidney volume (in mL; assessed with MRI) baseline vs day 56
    Kidney Function
    Change in estimated glomerular filtration rate (eGFR) according to CKD-EPI; baseline vs day 56

    Full Information

    First Posted
    September 29, 2023
    Last Updated
    October 20, 2023
    Sponsor
    Universitair Ziekenhuis Brussel
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06100133
    Brief Title
    Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
    Acronym
    ADKETONE
    Official Title
    Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    November 2023 (Anticipated)
    Primary Completion Date
    December 2024 (Anticipated)
    Study Completion Date
    July 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Universitair Ziekenhuis Brussel

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The investigators are running a study to see if a special drink, called a "ketone ester", can help people with a type of kidney disease named "Autosomal Dominant Polycystic Kidney Disease" or ADPKD for short. The investigators want to find out: If it's easy for patients to take this drink every day for about 2 months. If it's safe and doesn't cause any problems. If it makes a difference in the size and function of the kidneys. Who can join? People between 16 to 70 years old who have ADPKD. Those with a certain amount of kidney size and function. People who haven't been on specific diets or lost a lot of weight recently. Women who are not breastfeeding and are using birth control. People with a body weight that is not too low or too high. Who cannot join? People who've been on a high-fat diet or skipped meals for a while recently. Those with other health conditions like diabetes or certain metabolic issues. Anyone who has a problem with getting an MRI scan. If participants are in another medical study right now. The study will happen in two Belgian hospitals and is supported by the UZ Brussel's nephrology department. The investigators hope to include 20 people and start in November 2023.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    ADPKD
    Keywords
    ketone ester

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Model Description
    Repeated measures design to register the changes before and after treatment. Non-randomized, non-blinded, multi center prospective interventional cohort trial.
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Ketone Ester
    Arm Type
    Experimental
    Arm Description
    Up to 100g ketone ester daily for 56 days
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Ketone ester
    Other Intervention Name(s)
    (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (Ketone Ester)
    Intervention Description
    Up to 100g ketone ester daily for 56 days
    Primary Outcome Measure Information:
    Title
    Observance
    Description
    Objective observance (ketone body levels ≥0.8 mmol/l in ≥75% of blood measurements and ≥60% of maximal theoretic dose determined by used packages and self-report)
    Time Frame
    56 days
    Title
    Feasibility
    Description
    Patient reported feasibility, defined as a cohen d effect size of < 0.5 in the ADPKD impact scale.Both targets (observance and self-reported feasibility) must be met to reach the endpoint.
    Time Frame
    56 days
    Secondary Outcome Measure Information:
    Title
    Total Kidney Volume
    Description
    Change in Total kidney volume (in mL; assessed with MRI) baseline vs day 56
    Time Frame
    56 days
    Title
    Kidney Function
    Description
    Change in estimated glomerular filtration rate (eGFR) according to CKD-EPI; baseline vs day 56
    Time Frame
    56 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    16 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: - ADPKD patients (diagnosis based on genetics or imaging) ≥ 16 and ≤ 70 years. Total Kidney Volume ≥ 600 mL. eGFR (CKD-EPI) ≥ 30 ml/min/1.73m2. Normal blood glucose, HbA1C and ketones. Women of childbearing potential who are non-lactating and using an effective form of birth control. Stable disease-modifying treatment for the last 2 months. Well controlled hypertension (stable antihypertensive medications for at least 2 months). BMI > 18 < 30. Written informed consent. Exclusion Criteria: Exposure to a ketogenic diet or intermittent fasting for more than 2 weeks within 6 months before inclusion. Significant weight-loss (> 10%) within 6 months before inclusion. Diabetes mellitus. Conditions prohibiting the use of a ketogenic diet (liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/neogenesis, hyperinsulinism), based on patient history. Diagnosis with any disorder of fatty acid metabolism based on patient history. Eating disorder. Alcohol abuse. Contraindication for MRI. Participation in other interventional trial.

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?

    We'll reach out to this number within 24 hrs